Navitor Pharmaceuticals Obtains $23,500,000 Series A Funding

  • Feed Type
  • Date
    6/20/2014
  • Company Name
    Navitor Pharmaceuticals
  • Mailing Address
    700 Main Street Cambridge, MA 02139 USA
  • Company Description
    New scientific insights are emerging regarding the primal signaling pathways that direct an organism’s metabolic response to conditions in its environment—such as dynamic changes in the availability of nutrients, energy, oxygen and other factors—and the role of these metabolic signaling pathways in disease.
  • Website
    http://www.navitorpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $23,500,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient signaling via the mTORC1 pathway to address a wide range of diseases, including metabolic.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy